MiNK Therapeutics Past Earnings Performance
Past criteria checks 0/6
MiNK Therapeutics has been growing earnings at an average annual rate of 2.3%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been declining at an average rate of 158.5% per year.
Key information
2.3%
Earnings growth rate
12.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -158.5% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05Revenue & Expenses Breakdown
How MiNK Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -14 | 6 | 8 |
| 30 Jun 24 | 0 | -17 | 6 | 11 |
| 31 Mar 24 | 0 | -21 | 7 | 14 |
| 31 Dec 23 | 0 | -22 | 7 | 15 |
| 30 Sep 23 | 0 | -25 | 7 | 18 |
| 30 Jun 23 | 0 | -26 | 7 | 21 |
| 31 Mar 23 | 0 | -26 | 7 | 22 |
| 31 Dec 22 | 0 | -28 | 8 | 23 |
| 30 Sep 22 | 0 | -26 | 8 | 21 |
| 30 Jun 22 | 0 | -34 | 7 | 18 |
| 31 Mar 22 | 0 | -34 | 6 | 16 |
| 31 Dec 21 | 0 | -30 | 5 | 14 |
| 30 Sep 21 | 0 | -26 | 2 | 11 |
| 30 Jun 21 | 0 | -18 | 2 | 10 |
| 31 Mar 21 | 0 | -16 | 1 | 9 |
| 31 Dec 20 | 0 | -16 | 1 | 10 |
| 31 Dec 19 | 1 | -24 | 4 | 20 |
Quality Earnings: INKT is currently unprofitable.
Growing Profit Margin: INKT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INKT is unprofitable, but has reduced losses over the past 5 years at a rate of 2.3% per year.
Accelerating Growth: Unable to compare INKT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INKT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: INKT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.